metricas
covid
Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Benefit of sentinel node biopsy in patients with breast ductal carcinoma in situ
Journal Information
Vol. 85. Issue 2.
Pages 92-95 (February 2009)
Share
Share
Download PDF
More article options
Vol. 85. Issue 2.
Pages 92-95 (February 2009)
Full text access
Benefit of sentinel node biopsy in patients with breast ductal carcinoma in situ
Beneficio de la biopsia del ganglio linfático centinela en pacientes con carcinoma in situ de mama
Visits
1279
Isabel T. Rubioa,
Corresponding author
itrubio@yahoo.com

Author for correspondence.
, Isabel Rocab, Dolors Sabadella, Jordi Xercavinsa
a Unidad de Patología Mamaria, Hospital Universitario Vall d’Hebron, Barcelona, Spain
b Servicio de Medicina Nuclear, Hospital Vall d’Hebron, Barcelona, Spain
This item has received
Article information
Abstract
Introduction

Patients with a diagnosis of breast ductal carcinoma in situ (DCIS) have a low risk of developing axillary metastases. The use of sentinel node biopsy in this group of patients is controversial. The objective of this study is to determine if the sentinel node biopsy benefits a subgroup of patients with DCIS.

Patients and method

Between April 2002 and December 2007, patients with a diagnosis of DCIS and who underwent a sentinel node biopsy were included in the study. In our centre the sentinel node biopsy was performed in patients with DCIS who required a mastectomy, high grade and >2cm DCIS, and palpable DCIS.

Results

Forty-seven patients were included in the study. In all cases the sentinel node was identified. Twenty-five (53.1%) patients underwent a mastectomy due to extensive DCIS; 14 of these (56%) with immediate reconstruction with implants. Twenty-five (53.1%) patients had high grade DCIS. In 7 (14.8%) patients the tumour was palpable. Fourteen patients (29.7%) were upgraded to invasive breast cancer in the definitive histology. In 2 (4.2%) patients who underwent a mastectomy a positive sentinel node was found.

Conclusions

Performing sentinel node biopsy in this group of DCIS patients has lead us to identify 4% of patients with positive sentinel nodes. Furthermore, 29.7% of the patients have avoided a second invasive diagnostic procedure for definitive histology. For these reasons we consider it appropiate to perform sentinel node biopsy in this subgroup of patients with DCIS of the breas

Keywords:
Ductal carcinoma in situ
Breast
Sentinel node biopsyy
Resumen
Introducción

Las pacientes con carcinoma ductal in situ (CDIS) de la mama tienen un riesgo de metástasis ganglionares bajo. Las indicaciones de la utilización del ganglio centinela en el CDIS son controvertidas. El objetivo de este estudio es determinar si la biopsia del ganglio centinela beneficia a un grupo determinado de pacientes con CDIS.

Pacientes y método

Se ha incluido a las pacientes diagnosticadas de CDIS y con biopsia del ganglio centinela entre abril de 2002 y diciembre de 2007. En nuestro servicio, el protocolo para realizar ganglio centinela en CDIS ha sido CDIS extenso que requiera mastectomía, de alto grado y tamaño >2cm, y los CDIS que se acompañan de tumor palpable.

Resultados

Se incluyó a 47 pacientes. Se identificó el ganglio centinela en todos los casos. En 25 (53%) pacientes se realizó una mastectomía por CDIS extenso, y en 14 (56%) de estas pacientes se realizó reconstrucción inmediata. En 25 (53%) pacientes el CDIS fue de grado histológico alto (III). En 7 pacientes la lesión fue palpable. En el diagnóstico histopatológico final se observó que en 14 (29%) pacientes apareció carcinoma invasivo en el diagnóstico definitivo. En 2 (4%) pacientes con mastectomía se encontró un ganglio centinela positivo.

Conclusiones

Las indicaciones seguidas en el protocolo permiten identificar un 4% de ganglios centinelas positivos. Además, en el 29% de las pacientes cuya anatomía patológica definitiva muestra invasión se evita una segunda intervención quirúrgica. Por todo ello, creemos recomendable la realización de la biopsia del ganglio centinela en estos casos determinados de CDIS.

Palabras clave:
Carcinoma ductal in situ
Mama
Biopsia del ganglio centinela
Full text is only aviable in PDF
References
[1.]
M. Valenzuela, T.B. Julian.
Ductal carcinoma in situ: biology, diagnosis, and new therapies.
Clin Breast Cancer, 7 (2007), pp. 676-681
[2.]
N.N. Baxter, B.A. Virnig, S.B. Dirham, T.M. Tuttle.
Trenes in the treatment of ductal carcinoma in situ of the breast.
J Natl Cancer Inst, 96 (2004), pp. 443-448
[3.]
G.F. Schwartz, A.E. Giuliano, U. Veronesi.
Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast.
Cancer, 94 (2002), pp. 2542-2551
[4.]
G.H. Lyman, A.E. Giuliano, M.R. Somerfield, A.L. Benson, D.C. Bodurka, H.J. Burstein, et al.
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.
J Clin Oncol, 23 (2005), pp. 7703-7720
[5.]
A. Piñero, J. Jiménez, B. Merck, C. Vazquez.
Reuniónde Consenso sobre la Biopsia Selectiva del Ganglio Centinela en el Cáncer de Mama Sociedad Española de Senología y Patología Mamaria.
Cir Esp, 82 (2007), pp. 146-149
[6.]
S.E. Singletary, J.L. Conolly.
Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual.
CA Cancer J Clin, 56 (2006), pp. 37-47
[7.]
H.S. Cody III.
Sentinel lymph node biopsy for breast cancer: does anybody not need one?.
Ann Surg Oncol, 10 (2003), pp. 1131-1132
[8.]
C.E Cox, K. Nguyen, R.J. Gray, C. Salud, N.N. Ku, E. Dupont, et al.
Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?.
Am Surg, 67 (2001), pp. 513-518
[9.]
T.A. Kelly, J.A. Kim, R. Patrick, S. Grundfest, J.P. Crowe.
Axillary lymph node metastasis in patients with a final diagnosis of ductal carcinoma in situ.
Am J Surg, 186 (2003), pp. 368-370
[10.]
S. Pendas, E. Dauway, A.E. Giuliano, N. Ku, C.E. Cox, D.S. reingten.
Sentinel node biopsy in ductal carcinoma in situ patients.
Ann Surg Oncol, 7 (2000), pp. 15-20
[11.]
N. Klauber-DeMore, L.K. Tan, L. Liberman, S. Kaptain, J. Fey, P. Borgen, et al.
Sentinel lymph node biopsy:is it indicated in patients with high risk ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?.
Ann Surg Oncol, 7 (2000), pp. 636-642
[12.]
C. Wilkie, L. White, E. Dupont, A. Cantor, C.E. Cox.
An update on sentinel lymph node mapping in patients with ductal carcinoma in situ.
Am J Surg, 190 (2005), pp. 563-566
[13.]
M. Intra, P. Veronesi, G. Mazzarol, V. Galimberti, A. Luini, V. Sacchini, et al.
Axillary sentinel node biopsy in patients with pure DCIS of the breast.
Arch Surg, 138 (2003), pp. 309-313
[14.]
G.F. Schwartz, A.S. Patchefsky, S.D. Finklestein, S.H. Sohn, A. Prestipino, S.A. Feig, et al.
Nonpalpable in situ ductal carcinoma of the breast Predictors of multicentricity and microinvasion and implications for treatment.
Arch Surg., 124 (1989), pp. 29-32
[15.]
T.W. Yen, K.K. Hunt, M.I. Ross, N.Q. Mirza, G.V. Babiera, F. Meric- Bernstam, et al.
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph nodebiopsy in mamagement of ductal carcinoma in situ.
J Am Coll Surg, 200 (2005), pp. 516-526
[16.]
C. Tunon-de-Lara, S. Giard, M. Buttarelli, J. Blanchot, J.M. Classe, M. Baron, et al.
Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
[17.]
B. Ansari, S.A. Ogston, C.A. Purdie, D.J. Adamson, D.C. Brown, A.M. Thompson.
Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast.
Br J Surg, 95 (2008), pp. 547-554
[18.]
R.E. Ellsworth, D.L. Ellsworth, B. Love, H.L. Patney, L.R. Hoffman, J. Kane, et al.
Correlation of levels and patterns of genomic instability with histological grading of DCIS.
Ann Surg Oncol, 14 (2007), pp. 3070-3077
[19.]
S.L. Wong, M.J. Edwards, C. Chao, T.M. Tuttle, R.D. Noyes, D.J. Carlson, et al.
The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy.
Ann Surg Oncol., 9 (2002), pp. 272-277
Copyright © 2009. Asociación Española de Cirujanos
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos